Page 130 - 《中国药房》2025年19期

plus teclistamab in relapsed or refractory multiple mye- metastatic uveal melanoma[J]. N Engl J Med，2023，389
loma[J]. N Engl J Med，2025，392（2）：138-149. （24）：2256-2266.
[21] TOMASSON M H，IIDA S，NIESVIZKY R，et al. Long- [33] LEE D W，GARDNER R，PORTER D L，et al. Current
term survival and safety of elranatamab in patients with re‐ concepts in the diagnosis and management of cytokine re‐
lapsed or refractory multiple myeloma：update from the lease syndrome[J]. Blood，2014，124（2）：188-195.
MagnetisMM-3 study[J]. Hemasphere，2024，8（7）：e136. [34] FALCHI L，VARDHANA S A，SALLES G A. Bispecific
[22] ZHOU C C，TANG K J，CHO B C，et al. Amivantamab antibodies for the treatment of B-cell lymphoma：promi-
plus chemotherapy in NSCLC with EGFR exon 20 inser‐ ses，unknowns，and opportunities[J]. Blood，2023，141
tions[J]. N Engl J Med，2023，389（22）：2039-2051. （5）：467-480.
[23] CHOUAID C，BOSQUET L，KNOTT C，et al. Real-world [35] 梁良，金鹏飞，王婷，等. 托珠单抗治疗细胞因子释放综
frontline treatments in patients with advanced non-small- 合征的文献分析[J]. 临床药物治疗杂志，2020，18（3）：
cell lung cancer harboring epidermal growth factor recep‐ 26-30.
tor exon 20 insertions and adjusted comparisons versus [36] BRUDNO J N，KOCHENDERFER J N. Current under‐
amivantamab plus chemotherapy from the PAPILLON standing and management of CAR T cell-associated toxici‐
study[J]. Lung Cancer，2025，203：108548. ties[J]. Nat Rev Clin Oncol，2024，21（7）：501-521.
[24] WANG K W，DU R，MYALL N J，et al. Real-world effi‐ [37] FALCHI L，HUTCHINGS M，CARLO-STELLA C，et al.
cacy and safety of amivantamab for EGFR-mutant NSCLC Dexamethasone is associated with reduced frequency and
[J]. J Thorac Oncol，2024，19（3）：500-506. intensity of cytokine release syndrome compared with al‐
[25] DHILLON S. Ivonescimab：first approval[J]. Drugs， ternative corticosteroid regimens as premedication for
2024，84（9）：1135-1142. glofitamab in patients with relapsed/refractory large B-cell
[26] XIONG A W，WANG L，CHEN J H，et al. Ivonescimab lymphoma[J]. Haematologica，2025，110（4）：999-1004.
versus pembrolizumab for PD-L1-positive non-small cell [38] 国家卫生健康委员会. 血液肿瘤治疗药物的临床应用：
lung cancer（HARMONi-2）：a randomised，double-blind， 2022版新型抗肿瘤药物临床应用指导原则：四[J]. 中国
phase 3 study in China[J]. Lancet，2025，405（10481）： 合理用药探索，2023，20（7）：29-48.
839-849. [39] MORRIS E C，NEELAPU S S，GIAVRIDIS T，et al. Cyto‐
[27] CHEN Z W，WU L，WANG Q M，et al. Brief report： kine release syndrome and associated neurotoxicity in can‐
ivonescimab combined with etoposide plus carboplatin as cer immunotherapy[J]. Nat Rev Immunol，2022，22（2）：
first-line treatment for extensive-stage SCLC：results of a 85-96.
phase 1b clinical trial[J]. J Thorac Oncol，2025，20（2）： [40] WATTANA M K，ROWLAND J，QDAISAT A，et al. Di‐
233-239. agnosis and management of bispecific T cell-engaging an‐
[28] ZHANG Y X，HUANG Y，YANG Y P，et al. Iparomlimab tibody toxicity：a primer for emergency physicians[J].
and tuvonralimab（QL1706）plus chemotherapy and beva‐ Cancer Treat Rev，2025，134：102889.
cizumab for EGFR-mutant patients with advanced non- [41] HAMMONS L，SZABO A，JANARDAN A，et al. The
small cell lung cancer after failure of EGFR-tyrosine ki‐ changing spectrum of infection with BCMA and GPRC5D
nase inhibitors：updated results from cohort 5 in the targeting bispecific antibody（BsAb）therapy in patients
DUBHE-L-201 study[J]. J Hematol Oncol， 2025， with relapsed refractory multiple myeloma[J]. Haemato‐
18（1）：75. logica，2024，109（3）：906-914.
[29] GAO X Y，XU N，LI Z Y，et al. Safety and antitumour ac‐ [42] JOURDES A，CELLERIN E，TOUZEAU C，et al. Charac‐
tivity of cadonilimab，an anti-PD-1/CTLA-4 bispecific an‐ teristics and incidence of infections in patients with mul‐
tibody， for patients with advanced solid tumours tiple myeloma treated by bispecific antibodies：a national
（COMPASSION-03）：a multicentre，open-label，phase 1b/ retrospective study[J]. Clin Microbiol Infect，2024，30（6）：
2 trial[J]. Lancet Oncol，2023，24（10）：1134-1146. 764-771.
[30] CHEN J，YU H J，LIN Y T，et al. Real-world data of ca‐ [43] GONUGUNTA A S，MOHLERE V，ABID M B. Risk of
donilimab in recurrent or metastatic cervical cancer in infections with bispecific antibodies in B-cell non-
China：a multicentric study[J]. Front Immunol，2025，16： Hodgkin lymphomas and multiple myeloma：the current
1611696. state[J]. Br J Haematol，2024，205（3）：1197-1201.
[31] CARVAJAL R D，SACCO J J，JAGER M J，et al. Ad‐ [44] 国家癌症中心，中国药师协会肿瘤专科药师分会，赫捷，
vances in the clinical management of uveal melanoma[J]. 等. 抗体类抗肿瘤药物药学服务指南[J]. 中华肿瘤杂志，
Nat Rev Clin Oncol，2023，20（2）：99-115. 2022，44（10）：1017-1046.
[32] HASSEL J C，PIPERNO-NEUMANN S，RUTKOWSKI （收稿日期：2025-05-27 修回日期：2025-08-27）
P，et al. Three-year overall survival with tebentafusp in （编辑：唐晓莲）

· 2472 · China Pharmacy 2025 Vol. 36 No. 19 中国药房 2025年第36卷第19期